Colorectal Cancer RECHALLENGE

Inclusion criteria: * Histologically proven adenocarcinoma of colon or rectum * Measurable metastatic disease, either inoperable, or residual after surgical procedure * No prior chemotherapy for metastatic disease * For colon cancer: prior adjuvant chemotherapy with oxaliplatin that ended at least 12 months prior to enrollment. * For rectal cancer: at least 12 months since prior use of oxaliplatin in neoadjuvant or adjuvant chemotherapy * Adequate liver and kidney function: * Total bilirubin inferior to 1.5 ULN * Serum Creatinine inferior to 150 umol/L * Creatinine clearance (ClCr) \> 30 mL/min * ALT / AST inferior to 3 ULN * Adequate hematological function * Neutrophils \> or equal 1.5 x 109/L * Platelets \> or equal 100 x 109/L Exclusion criteria: * Metastatic disease presenting without prior adjuvant chemotherapy * Metastatic disease presenting after non-oxaliplatin-containing adjuvant chemotherapy * Peripheral sensory or motor neuropathy \> grade 1 * Eastern Cooperative Oncology Group (ECOG) Performance status \> 2 * Other active malignancy * History of known allergy to oxaliplatin or other platinum compounds, to 5-FU, to Leucovorin or to any ingredients in the formulations or the containers * Patients who are pregnant, or breast-feeding * Patients with severe renal impairment (ClCr \< 30 mL/min) * Pernicious anemia or other megaloblastic anemia with Vitamin B12 deficiency * Patients with reproductive potential not implementing accepted and effective method of contraception (the definition of effective method of contraception will be based on the investigators' judgment) * Participation in another clinical trial with any investigational drug within 30 days prior to study screening * For patient who will receive Bevacizumab: Bevacizumab is contraindicated in patients with know hypersensitivity to any components of the product and to Chinese hamster ovary cell product or other recombinant human or humanized antibodies * Presence of any symptoms suggesting brain metastasis The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.